245 related articles for article (PubMed ID: 26494789)
1. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Dai H; Ding H; Meng XW; Peterson KL; Schneider PA; Karp JE; Kaufmann SH
Genes Dev; 2015 Oct; 29(20):2140-52. PubMed ID: 26494789
[TBL] [Abstract][Full Text] [Related]
2. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
4. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
5. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane.
O'Neill KL; Huang K; Zhang J; Chen Y; Luo X
Genes Dev; 2016 Apr; 30(8):973-88. PubMed ID: 27056669
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
9. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.
Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G
Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208
[TBL] [Abstract][Full Text] [Related]
10. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.
Liu D; Hou X; Wu W; Zanfagnin V; Li Y; Correia C; Zhao Z; Zhao C; Liu Z; Zhang T; Fang Z; Wang H; Xu C; Weroha SJ; Kaufmann SH; Dai H
Cell Death Dis; 2021 Aug; 12(8):789. PubMed ID: 34385422
[TBL] [Abstract][Full Text] [Related]
11. Caspase-mediated Bak activation and cytochrome c release during intrinsic apoptotic cell death in Jurkat cells.
Shawgo ME; Shelton SN; Robertson JD
J Biol Chem; 2008 Dec; 283(51):35532-8. PubMed ID: 18927073
[TBL] [Abstract][Full Text] [Related]
12. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L).
Lindenboim L; Blacher E; Borner C; Stein R
Cell Death Differ; 2010 Feb; 17(2):346-59. PubMed ID: 19816507
[TBL] [Abstract][Full Text] [Related]
13. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.
Ilyas SI; Mertens JC; Bronk SF; Hirsova P; Dai H; Roberts LR; Kaufmann SH; Gores GJ
J Biol Chem; 2014 Aug; 289(33):22835-22849. PubMed ID: 24973208
[TBL] [Abstract][Full Text] [Related]
15. Pan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak.
Song T; Xue Z; Zhang Z; Shen X; Li X
Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):145-51. PubMed ID: 23557083
[TBL] [Abstract][Full Text] [Related]
16. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition.
Shimazu T; Degenhardt K; Nur-E-Kamal A; Zhang J; Yoshida T; Zhang Y; Mathew R; White E; Inouye M
Genes Dev; 2007 Apr; 21(8):929-41. PubMed ID: 17403773
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the BH3-only protein Puma as a direct Bak activator.
Dai H; Pang YP; Ramirez-Alvarado M; Kaufmann SH
J Biol Chem; 2014 Jan; 289(1):89-99. PubMed ID: 24265320
[TBL] [Abstract][Full Text] [Related]
18. Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design.
Brouwer JM; Lan P; Cowan AD; Bernardini JP; Birkinshaw RW; van Delft MF; Sleebs BE; Robin AY; Wardak A; Tan IK; Reljic B; Lee EF; Fairlie WD; Call MJ; Smith BJ; Dewson G; Lessene G; Colman PM; Czabotar PE
Mol Cell; 2017 Nov; 68(4):659-672.e9. PubMed ID: 29149594
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
20. Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis.
Rudner J; Elsaesser SJ; Jendrossek V; Huber SM
Biochem Pharmacol; 2011 Jan; 81(1):32-42. PubMed ID: 20836993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
